CCL1 in therapy



Pharmaceuticals and Biotechnology

The Technology

In inflammatory autoimmune disease such as Inflammatory Bowels diseases (IBD) Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and others the activity of effector autoimmune T cells is tightly regulated by FOXp3+ regulatory T cells (Tregs). CCL1 is a chemokine with a very short half-life time (in vivo) that exclusively potentiates the activity of these cells. We have generated a CCL1-Ig based fusion protein (also referred to as CCL1-Fc) with a substantially longer half-life in vivo (PK) and a very long in vivo activity (PD) that function as an agonistic molecule for FOXP3+ Tregs and effectively suppresses ongoing autoimmunity.


  • Effectively treats different autoimmune diseases in experimental models (EAE, IBD)
  • As an agonistic molecule, has a long half life time
  • Likely to have low toxicity
  • Robust in vitro and ex-vivo assays relevant to the MOA of the drug.

Applications and Opportunities

  • Autoimmunity, chronic inflammation
arrow Business Development Contacts
Motti Koren
Director of Business Development, Life Sciences